Global Aflibercept Biosimilars Competitive Landscape Professional Research Report 2024

Global Aflibercept Biosimilars Competitive Landscape Professional Research Report 2024

Research Summary

Aflibercept biosimilars are biologic medical products highly similar to the original aflibercept (marketed as Eylea), which is an anti-VEGF (vascular endothelial growth factor) therapy used primarily to treat various retinal diseases, including age-related macular degeneration (AMD) and diabetic retinopathy. These biosimilars undergo rigorous testing to demonstrate their equivalence in terms of safety, efficacy, and quality to the reference product, providing more cost-effective treatment options while maintaining therapeutic benefits for patients suffering from serious eye conditions that can lead to vision loss.

According to DIResearch's in-depth investigation and research, the global Aflibercept Biosimilars market size will reach XX US$ Million in 2024, and is expected to reach XX US$ Million in 2030, with a CAGR of XX% (2025-2030). Among them, the China market has changed rapidly in the past few years. The market size in 2024 will be XX US$ Million, accounting for approximately XX% of the world. It is expected to reach XX US$ Million in 2030, and the global share will reach XX%.

The major global manufacturers of Aflibercept Biosimilars include Bayer, Roche, Regeneron, Sanofi, Novartis, Sartorius, Amgen, Samsung Bioepis, Mylan, Formycon, Coherus BioSciences, Cadila Pharmaceuticals, Hetero, Biocon, Gene Techno Science, Qilu Pharmaceutical etc. The global players competition landscape in this report is divided into three tiers. The first tiers is the global leading enterprise, which occupies a major market share, is in a leading position in the industry, has strong competitiveness and influence, and has a large revenue scale; the second tiers has a certain share and popularity in the market, actively follows the industry leaders in product, service or technological innovation, and has a medium revenue scale; the third tiers has a smaller share in the market, has a lower brand awareness, mainly focuses on the local market, and has a relatively small revenue scale.

This report studies the market size, price trends and future development prospects of Aflibercept Biosimilars. Focus on analysing the market share, product portfolio, prices, sales volume, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Aflibercept Biosimilars market. The report data covers historical data from 2019 to 2023, based year in 2024 and forecast data from 2025 to 2030.

The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the Aflibercept Biosimilars market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Aflibercept Biosimilars industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.

The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.

Global Key Manufacturers of Aflibercept Biosimilars Include:

Bayer

Roche

Regeneron

Sanofi

Novartis

Sartorius

Amgen

Samsung Bioepis

Mylan

Formycon

Coherus BioSciences

Cadila Pharmaceuticals

Hetero

Biocon

Gene Techno Science

Qilu Pharmaceutical

Aflibercept Biosimilars Product Segment Include:

Intravitreal Injection

Intravenous Injection

Aflibercept Biosimilars Product Application Include:

Wet Macular Degeneration

Metastatic Colorectal Cancer

Chapter Scope

Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends

Chapter 2: Global Aflibercept Biosimilars Industry PESTEL Analysis

Chapter 3: Global Aflibercept Biosimilars Industry Porter’s Five Forces Analysis

Chapter 4: Global Aflibercept Biosimilars Major Regional Market Size (Revenue, Sales, Price) and Forecast Analysis

Chapter 5: Global Aflibercept Biosimilars Market Size and Forecast by Type and Application Analysis

Chapter 6: North America Aflibercept Biosimilars Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 7: Europe Aflibercept Biosimilars Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 8: China Aflibercept Biosimilars Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 9: APAC (Excl. China) Aflibercept Biosimilars Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 10: Latin America Aflibercept Biosimilars Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 11: Middle East and Africa Aflibercept Biosimilars Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 12: Global Aflibercept Biosimilars Competitive Analysis of Key Manufacturers (Sales, Revenue, Market Share, Price, Regional Distribution and Industry Concentration)

Chapter 13: Key Company Profiles (Product Portfolio, Sales, Revenue, Price and Gross Margin)

Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers

Chapter 15: Research Findings and Conclusion

Chapter 16: Methodology and Data Sources